Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

The Safety and Clinical Efficacy of Dasatinib Plus Human CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Subjects With Ph-positive Acute Lymphoblastic Leukemia

Authors not listed

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 2021

Abstract

To evaluate the safety and efficacy of Dasatinib plus CD19/CD22 Bispecific CAR-T for the treatment of elderly Ph-positive lymphoblastic leukemia. Newly diagnosed Ph-positive patients will be given Dasatinib plus VP chemotherapy for induction treatment,if a hematologic complete remission was observed then a lymphocyte collection will be administrated to patients. Then chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-10 MST

Cite this

APA
Anonymous. (2021). The Safety and Clinical Efficacy of Dasatinib Plus Human CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Subjects With Ph-positive Acute Lymphoblastic Leukemia. <em>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</em>. https://clinicaltrials.gov/study/NCT05523661
Vancouver
Anonymous. The Safety and Clinical Efficacy of Dasatinib Plus Human CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Subjects With Ph-positive Acute Lymphoblastic Leukemia. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. 2021.
BibTeX
@misc{anon2021TheSaf, title = {The Safety and Clinical Efficacy of Dasatinib Plus Human CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Subjects With Ph-positive Acute Lymphoblastic Leukemia}, author = {Anonymous}, journal = {Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine}, year = {2021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings